Abstract
The triple drug combination consisting of irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) has demonstrated higher activity and efficacy compared to the doublet FOLFIRI. 5-Fluorouracil could be substituted in FOLFOXIRI regimen by capecitabine, an oral fluoropyrimidine with similar efficacy. Recently, a dose-finding trial has demonstrated the feasibility of the combination of irinotecan, oxaliplatin and capecitabine (XELOXIRI) and established their recommended doses. The aim of this study was to evaluate the activity of XELOXIRI. A total of 36 patients with unresectable metastatic colorectal cancer received irinotecan 165 mg m 2 and oxaliplatin 85 mg m 2 on day 1 plus capecitabine 2000 mg m 2 per day orally in two doses from day 1 to day 7, every 2 weeks. Grade 3-4 toxicities were infrequent, expect for neutropenia and diarrhoea, which were each observed in 30% of patients. Two complete and twenty-two partial responses were obtained, corresponding to an overall response rate of 67% (95% CI 51.4-82%). After a median follow-up of 17.7 months, the median progression-free and overall survival were 10.1 and 17.9 months, respectively.The substitution of 5-fluorouracil with capecitabine, in combination with irinotecan and oxaliplatin, is feasible and does not impair the activity of the regimen. However, the XELOXIRI combination is associated with a high incidence of diarrhoea and, therefore, should be considered as a not preferable alternative to FOLFOXIRI.
| Original language | English |
|---|---|
| Pages (from-to) | 1720-1724 |
| Number of pages | 5 |
| Journal | British Journal of Cancer |
| Volume | 100 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Jun 2 2009 |
Fingerprint
Keywords
- First-line treatment
- Metastatic colorectal cancer
- Triple drug combination
- XELOXIRI
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. / Vasile, E.; Masi, G.; Fornaro, L.; Cupini, S.; Loupakis, F.; Bursi, S.; Petrini, I.; Di Donato, S.; Brunetti, I. M.; Ricci, S.; Antonuzzo, A.; Chiara, S.; Amoroso, D.; Andreuccetti, M.; Falcone, A.
In: British Journal of Cancer, Vol. 100, No. 11, 02.06.2009, p. 1720-1724.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
AU - Vasile, E.
AU - Masi, G.
AU - Fornaro, L.
AU - Cupini, S.
AU - Loupakis, F.
AU - Bursi, S.
AU - Petrini, I.
AU - Di Donato, S.
AU - Brunetti, I. M.
AU - Ricci, S.
AU - Antonuzzo, A.
AU - Chiara, S.
AU - Amoroso, D.
AU - Andreuccetti, M.
AU - Falcone, A.
PY - 2009/6/2
Y1 - 2009/6/2
N2 - The triple drug combination consisting of irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) has demonstrated higher activity and efficacy compared to the doublet FOLFIRI. 5-Fluorouracil could be substituted in FOLFOXIRI regimen by capecitabine, an oral fluoropyrimidine with similar efficacy. Recently, a dose-finding trial has demonstrated the feasibility of the combination of irinotecan, oxaliplatin and capecitabine (XELOXIRI) and established their recommended doses. The aim of this study was to evaluate the activity of XELOXIRI. A total of 36 patients with unresectable metastatic colorectal cancer received irinotecan 165 mg m 2 and oxaliplatin 85 mg m 2 on day 1 plus capecitabine 2000 mg m 2 per day orally in two doses from day 1 to day 7, every 2 weeks. Grade 3-4 toxicities were infrequent, expect for neutropenia and diarrhoea, which were each observed in 30% of patients. Two complete and twenty-two partial responses were obtained, corresponding to an overall response rate of 67% (95% CI 51.4-82%). After a median follow-up of 17.7 months, the median progression-free and overall survival were 10.1 and 17.9 months, respectively.The substitution of 5-fluorouracil with capecitabine, in combination with irinotecan and oxaliplatin, is feasible and does not impair the activity of the regimen. However, the XELOXIRI combination is associated with a high incidence of diarrhoea and, therefore, should be considered as a not preferable alternative to FOLFOXIRI.
AB - The triple drug combination consisting of irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) has demonstrated higher activity and efficacy compared to the doublet FOLFIRI. 5-Fluorouracil could be substituted in FOLFOXIRI regimen by capecitabine, an oral fluoropyrimidine with similar efficacy. Recently, a dose-finding trial has demonstrated the feasibility of the combination of irinotecan, oxaliplatin and capecitabine (XELOXIRI) and established their recommended doses. The aim of this study was to evaluate the activity of XELOXIRI. A total of 36 patients with unresectable metastatic colorectal cancer received irinotecan 165 mg m 2 and oxaliplatin 85 mg m 2 on day 1 plus capecitabine 2000 mg m 2 per day orally in two doses from day 1 to day 7, every 2 weeks. Grade 3-4 toxicities were infrequent, expect for neutropenia and diarrhoea, which were each observed in 30% of patients. Two complete and twenty-two partial responses were obtained, corresponding to an overall response rate of 67% (95% CI 51.4-82%). After a median follow-up of 17.7 months, the median progression-free and overall survival were 10.1 and 17.9 months, respectively.The substitution of 5-fluorouracil with capecitabine, in combination with irinotecan and oxaliplatin, is feasible and does not impair the activity of the regimen. However, the XELOXIRI combination is associated with a high incidence of diarrhoea and, therefore, should be considered as a not preferable alternative to FOLFOXIRI.
KW - First-line treatment
KW - Metastatic colorectal cancer
KW - Triple drug combination
KW - XELOXIRI
UR - http://www.scopus.com/inward/record.url?scp=67349088298&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67349088298&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6605075
DO - 10.1038/sj.bjc.6605075
M3 - Article
C2 - 19436300
AN - SCOPUS:67349088298
VL - 100
SP - 1720
EP - 1724
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 11
ER -